The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
Open accessAbstract
Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective safety data at 1, 3, and 6 months poststudy was also collected. Delta-9-THC (1) produced schizophrenia-like positive and negative symptoms; (2) altered perception; (3) increased anxiety; (4) produced euphoria; (5) disrupted immediate and delayed word recall, sparing recognition recall; (6) impaired performance on tests of distractibility, verbal fluency, and working memory (7) did not impair orientation; (8) increased plasma cortisol. These data indicate that Delta-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses. These data warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is evidence to suggest a positive association between cannabis use and development of psychosis, in people susceptible to psychotic disorders.117–119”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [119]
In the citing paper
“Randomised controlled trials in laboratory conditions provide evidence that delta-9-tetrahydrocannabinol (THC), the main active compound in cannabis, can induce transient psychotic-like experiences (1).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
In the citing paper
“However, these experiences resolve within a few hours and rarely cause distress, in contrast to psychotic disorder where experiences are prolonged and impairment often substantial.”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
In the citing paper
“The experimental evidence showing that psychotic experiences occur during cannabis intoxication (1) indicates that cannabis has biological effects that could translate to chronic psychotic disorders.”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
Citations
Cites
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Role of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
Borkowski, J. G., Benton, A. L., & Spreen, O. (1967) · Neuropsychologia · doi:10.1016/0028-3932(67)90015-2 · Cited by 1,302
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts
Andréasson, S., Engström, A., Allebeck, P., & Rydberg, U. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92620-1 · Cited by 1,166
Tanda, G., Pontieri, F. E., & Chiara, G. D. (1997) · Science · doi:10.1126/science.276.5321.2048 · Cited by 1,080
Glass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291514 · Cited by 1,016 · cited 12×
“PANSS subscale scores, VAS scores, CADSS clinician, and CADSS subject ratings were analyzed using the %LD_F2 SAS macro (Brunner et al, 2002) with dose (placebo, low, high) and time (P10, P80, P200) as between-subject factors.”
MethodInfluentialCannabis use and psychosis: A longitudinal population-based study
van Os, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf043 · Cited by 928
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Self-citationMolecular cloning of a human cannabinoid receptor which is also expressed in testis
Gérard, C. M., Mollereau, C., Vassart, G., & Parmentier, M. (1991) · Biochemical Journal · doi:10.1042/bj2790129 · Cited by 687
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Nonparametric analysis of longitudinal data in factorial experiments
Brunner, E., Domhof, S., & Langer, F. (2002) · Cited by 635
Abnormal neural synchrony in schizophrenia
Spencer, K. M., Nestor, P. G., Niznikiewicz, M. A., Salisbury, D. F., Shenton, M. E., & McCarley, R. W. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-19-07407.2003 · Cited by 624
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Amphetamine Psychosis: A "Model" Schizophrenia Mediated by Catecholamines
SNYDER, S. H. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.1.61 · Cited by 587
Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations
Hájos, N., Katona, I., Naiem, S. S., Mackie, K., Ledent, C., Mody, I., & Freund, T. F. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00217.x · Cited by 533
Provocative tests with psychostimulant drugs in schizophrenia
Lieberman, J. A., Kane, J. M., & Alvir, J. (1987) · Psychopharmacology · doi:10.1007/bf00216006 · Cited by 532
Pharmacology of Cannabinoid Receptor Ligands
Pertwee, R. G. (1999) · Current Medicinal Chemistry · doi:10.2174/0929867306666220401124036 · Cited by 526
Huestis, M. A., Henningfield, J. E., & Cone, E. J. (1992) · Journal of Analytical Toxicology · doi:10.1093/jat/16.5.276 · Cited by 519
Ohlsson, A., Lindgren, J.-E., Wahlen, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. (1980) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1980.181 · Cited by 475
Psychiatric effects of cannabis
Johns, A. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.116 · Cited by 469
Elevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00008 · Cited by 432
The neurobiology and evolution of cannabinoid signalling
Elphick, M. R., & Egertova, M. (2001) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2000.0787 · Cited by 417
Agurell, S., Halldin, M., Lindgren, J. E., Ohlsson, A., Widman, M., Gillespie, H., & Hollister, L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06861-9 · Cited by 406 · cited 8×
“Test days were separated by at least 1 week (43 times the elimination half-life of D-9THC) to minimize carryover effects (Wall et al, 1976).”
MethodInfluentialMechanisms of Cannabinoid Inhibition of GABAASynaptic Transmission in the Hippocampus
Hoffman, A. F., & Lupica, C. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-07-02470.2000 · Cited by 399
Dean, B., Sundram, S., Bradbury, R., Scarr, E., & Copolov, D. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00552-2 · Cited by 383
Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
French, E. D., Dillon, K., & Wu, X. (1997) · NeuroReport · doi:10.1097/00001756-199702100-00014 · Cited by 374
Curran, V., Brignell, C., Fletcher, S., Middleton, P., & Henry, J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1169-0 · Cited by 369
Egertov�, M., & Elphick, M. R. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000626)422:2<159::aid-cne1>3.0.co;2-1 · Cited by 364
Laruelle, M. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00054-5 · Cited by 358
Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women
Wall, M. E., Sadler, B. M., Brine, D., Taylor, H., & Perez-Reyes, M. (1983) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1983.179 · Cited by 345
Tsou, K., Mackie, K., Sañudo-Peña, M. C., & Walker, J. M. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00086-x · Cited by 343
Egertová, M., Giang, D. K., Cravatt, B. F., & Elphick, M. R. (1998) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.1998.0543 · Cited by 334
Chen, J., Paredes, W., Li, J., Smith, D., Lowinson, J., & Gardner, E. L. (1990) · Psychopharmacology · doi:10.1007/bf02245916 · Cited by 329
Amphetamine psychosis: Behavioral and biochemical aspects
Angrist, B., Sathananthan, G., Wilk, S., & Gershon, S. (1974) · Journal of Psychiatric Research · doi:10.1016/0022-3956(74)90064-8 · Cited by 326
Potency Trends of Δ9-THC and Other Cannabinoids in Confiscated Marijuana from 1980–1997
ElSohly, M., Ross, S., Mehmedic, Z., Arafat, R., Yi, B., & Banahan, B. (2000) · Journal of Forensic Sciences · doi:10.1520/jfs14636j · Cited by 308
Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers
Adler, C., Goldberg, T., Malhotra, A., Pickar, D., & Breier, A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00556-8 · Cited by 304
Auclair, N., Otani, S., Soubrie, P., & Crepel, F. (2000) · Journal of Neurophysiology · doi:10.1152/jn.2000.83.6.3287 · Cited by 290
Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons
Misner, D. L., & Sullivan, J. M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-16-06795.1999 · Cited by 285
Effects of Acute Smoked Marijuana on Complex Cognitive Performance
Hart, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00273-1 · Cited by 271
Cannabis and Cognitive Functioning
Solowij, N. (1998) · Cambridge University Press eBooks · doi:10.1017/cbo9780511526824 · Cited by 269
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264
GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus
Katona, I., Sperlágh, B., Maglóczky, Z., Sántha, E., Köfalvi, A., Czirják, S., Mackie, K., Vizi, E. S., & Freund, T. F. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00286-4 · Cited by 244
French, E. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00278-4 · Cited by 236
CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
Ujike, H., Takaki, M., Nakata, K., Tanaka, Y., Takeda, T., Kodama, M., Fujiwara, Y., Sakai, A., & Kuroda, S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001029 · Cited by 228
Emrich, H. M., Leweke, F. M., & Schneider, U. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00426-1 · Cited by 226
Haertzen, C. A. (1966) · Psychological Reports · doi:10.2466/pr0.1966.18.1.163 · Cited by 223
Vollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223
Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication
Volkow, N. D., Gillespie, H., Mullani, N., Tancredi, L., Grant, C., Valentine, A., & Hollister, L. (1996) · Psychiatry Research: Neuroimaging · doi:10.1016/0925-4927(96)02817-x · Cited by 219
Tolerance and disposition of tetrahydrocannabinol in man.
Hunt, C. A., & Jones, R. T. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32251-2 · Cited by 219
Imaging subcortical auditory activity in humans
Guimarães, A. R., Melcher, J. R., Talavage, T. M., Baker, J. R., Ledden, P. J., Rosen, B. R., Kiang, N. Y.-S., Fullerton, B. C., & Weisskoff, R. M. (1998) · Human Brain Mapping · doi:10.1002/(sici)1097-0193(1998)6:1<33::aid-hbm3>3.0.co;2-m · Cited by 218
Compton, D. R., Johnson, M. R., Melvin, L. S., & Martin, B. R. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11216-0 · Cited by 215
Terranova, J.-P., Michaud, J.-C., Le Fur, G., & Soubrié, P. (1995) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00169393 · Cited by 206
Andréasson, S., Allebeck, P., Engström, A., & Rydberg, U. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91823-5 · Cited by 202
Effects of cannabidiol in animal models predictive of antipsychotic activity
Zuardi, A. W., Antunes Rodrigues, J., & Cunha, J. M. (1991) · Psychopharmacology · doi:10.1007/bf02244189 · Cited by 191
Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula
Ellison, G. (1994) · Brain Research Reviews · doi:10.1016/0165-0173(94)90012-4 · Cited by 182
Petitet, F., Jeantaud, B., Reibaud, M., Imperato, A., & Dubroeucq, M.-C. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00238-0 · Cited by 180
Comparative Effects of Alcohol and Marijuana on Mood, Memory, and Performance
Heishman, S. J., Arasteh, K., & Stitzer, M. L. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00456-x · Cited by 179
An integrated view of pathophysiological models of schizophrenia
Duncan, G. E., Sheitman, B. B., & Lieberman, J. A. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00002-8 · Cited by 176
Function of Cannabinoid Receptors in the Neuroendocrine Regulation of Hormone Secretion
Murphy, L. L., Muñoz, R. M., Adrian, B. A., & Villanúa, M. A. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0224 · Cited by 176
Sullivan, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.3.1286 · Cited by 173
Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids
Diana, M., Melis, M., & Gessa, G. L. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00292.x · Cited by 173
Cadoni, C., Pisanu, A., Solinas, M., Acquas, E., & Chiara, G. (2001) · Psychopharmacology · doi:10.1007/s002130100875 · Cited by 168
From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis
Mechoulam, R., & Ben‐Shabat, S. (1999) · Natural Product Reports · doi:10.1039/a703973e · Cited by 167
Δ9-Tetrahydroeannabinol enhances presynaptic dopamine efflux In medial prefrontal cortex
Jianping, C., Paredes, W. M., Lowinson, J. H., & Gardner, E. L. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)94136-l · Cited by 166
Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis
McGuire, P. K., Jones, P., Harvey, I., Williams, M., McGuffin, P., & Murray, R. M. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00053-b · Cited by 165
The Metabolism of Δ9‐Tetrahydrocannabinol and Related Cannabinoids in Man
Wall, M. E., & Perez‐Reyes, M. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02594.x · Cited by 162
Schizophrenia in users and nonusers of cannabis: A longitudinal study in Stockholm County
Andréasson, S., Allebeck, P., & Rydberg, U. S. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb10296.x · Cited by 160
Jentsch, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00018-3 · Cited by 158
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 157
The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats
Belue, R. C., Howlett, A. C., Westlake, T. M., & Hutchings, D. E. (1995) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(94)00053-g · Cited by 153
Lindgren, J., Ohlsson, A., Agurell, S., Hollister, L. E., & Gillespie, H. K. (1981) · Psychopharmacology · doi:10.1007/bf00427095 · Cited by 153
Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors
Böhme, G. A., Laville, M., Ledent, C. A., Parmentier, M., & Impérato, A. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00483-2 · Cited by 149
Metabolism of Tetrahydrocannabinol in Frequent and Infrequent Marijuana Users
Kelly, P., & Jones, R. T. (1992) · Journal of Analytical Toxicology · doi:10.1093/jat/16.4.228 · Cited by 148
Reinforcing and subjective effects of oral Δ9-THC and smoked marijuana in humans
Chait, L. D., & Zacny, J. P. (1992) · Psychopharmacology · doi:10.1007/bf02245145 · Cited by 143
Cannabis: Effects on memory and the cholinergic limbic system.
Miller, L. L., & Branconnier, R. J. (1983) · Psychological Bulletin · doi:10.1037/0033-2909.93.3.441 · Cited by 142
Chen, J., Paredes, W. M., Lowinson, J. H., & Gardner, E. L. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90739-g · Cited by 142
Gessa, G. L., Casu, M. A., Carta, G., & Mascia, M. S. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00486-5 · Cited by 142
Heishman, S. J., Huestis, M. A., Henningfield, J. E., & Cone, E. J. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90028-g · Cited by 138
Endocannabinoids in cognition and dependence
Lichtman, A. H., Varvel, S. A., & Martin, B. R. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0351 · Cited by 138
Gorriti, M. Á., de Fonseca, F. R., Navarro, M., & Palomo, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00851-6 · Cited by 137
Johansson, E., Norén, K., Sjövall, J., & Halldin, M. M. (1989) · Biomedical Chromatography · doi:10.1002/bmc.1130030109 · Cited by 136
Lamarque, S., Taghzouti, K., & Simon, H. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00039-9 · Cited by 133
Cannabis is more than simply Δ9-tetrahydrocannabinol
Russo, E. B., & McPartland, J. M. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1348-z · Cited by 125
Effects of long-term cannabis use on selective attention: An event-related potential study
Solowij, N., Michie, P. T., & Fox, A. M. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90382-c · Cited by 125
Melis, M., Gessa, G. L., & Diana, M. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00119-6 · Cited by 125
Acute and Residual Effects of Marijuana in Humans
Fant, R. V. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00386-9 · Cited by 122
Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs.
Azorlosa, J. L., Heishman, S. J., Stitzer, M. L., & Mahaffey, J. M. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10949-x · Cited by 117
Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A
Gessa, G. L., Mascia, M. S., Casu, M. A., & Carta, G. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)89683-5 · Cited by 112
The DSM-III-R Field Trial of Disruptive Behavior Disorders
Spitzer, R. L., Davies, M., & Barkley, R. A. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199009000-00003 · Cited by 107
Leweke, F. M., Schneider, U., Thies, M., Münte, T. F., & Emrich, H. M. (1999) · Psychopharmacology · doi:10.1007/s002130050884 · Cited by 102 · cited 2×
“…(Andreasson et al, 1987, 1988, 1989; Arseneault et al, 2002; McGuire et al, 1995; Zammit et al, 2002), genetic (Ujike et al, 2002), neurochemical (Leweke et al, 1999a), and postmortem (Dean et al, 2001) approaches, suggesting that the consumption of cannabinoids (exogenous) and/or brain…”
BackgroundResultEffects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation
Pistis, M., Porcu, G. S., Melis, M., Diana, M., & Gessa, G. L. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01612.x · Cited by 100
Cone, E. J., & Huestis, M. A. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199312000-00013 · Cited by 99
MARIHUANA-INDUCED "HIGH": INFLUENCE OF EXPECTATION, SETTING AND PREVIOUS DRUG EXPERIENCE
Jones, R. T. (1971) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06900-5 · Cited by 97
Nowicky, A. V., Teyler, T. J., & Vardaris, R. M. (1987) · Brain Research Bulletin · doi:10.1016/0361-9230(87)90052-9 · Cited by 96
Yui, K., Goto, K., Ikemoto, S., Ishiguro, T., Angrist, B., Duncan, G. E., Sheitman, B., Lieberman, J. A., Bracha, S., & Ali, S. F. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000575 · Cited by 95
Pistis, M., Muntoni, A. L., Pillolla, G., & Gessa, G. L. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02019.x · Cited by 94
Collins, D. R., Pertwee, R. G., & Davies, S. N. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15889.x · Cited by 92
Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze
Guimarães, F. S., Aguiar, J. C. D., Mechoulam, R., & Breuer, A. (1994) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(94)90027-2 · Cited by 89
Acquas, E., Pisanu, A., Marrocu, P., & Chiara, G. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00403-9 · Cited by 83
Cocchetto, D. M., Owens, S. M., Perez‐Reyes, M., Guiseppi, S. R. D., & Miller, L. L. (1981) · Psychopharmacology · doi:10.1007/bf00432179 · Cited by 83
Hooker, W. D., & Jones, R. T. (1987) · Psychopharmacology · doi:10.1007/bf00690920 · Cited by 82
Bornheim, L. M., Kim, K. Y., Li, J., Perotti, B. Y. T., & Benet, L. Z. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06664-4 · Cited by 79
Collins, D. R., Pertwee, R. G., & Davies, S. N. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90666-1 · Cited by 77
Marks, D. F., & MacAvoy, M. G. (1989) · Psychopharmacology · doi:10.1007/bf00445566 · Cited by 77
Nava, F. A., Carta, G., Colombo, G., & Gessa, G. L. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00075-2 · Cited by 77
Cannabis and Cannabinoids: Pharmacology and Rationale for Clinical Use
Pertwee, R. G. (1999) · Complementary Medicine Research · doi:10.1159/000057150 · Cited by 72
Is verbal recognition memory really different in Huntington's and Alzheimer's disease?
Brandt, J., Corwin, J., & Krafft, L. (1992) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688639208402862 · Cited by 72
Carta, G., Nava, F. A., & GESSA, G. L. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00738-0 · Cited by 67
Cannabinoid-induced Fos expression within A10 dopaminergic neurons
Patel, S., & Hillard, C. J. (2003) · Brain Research · doi:10.1016/s0006-8993(02)03797-6 · Cited by 63
Marijuana and memory impairment: Effect on free recall and recognition memory
Miller, L. L., McFarland, D. J., Cornett, T., & Brightwell, D. R. (1977) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(77)90191-5 · Cited by 62
Acquas, E., Pisanu, A., Marrocu, P., Goldberg, S. R., & Chiara, G. D. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00967-0 · Cited by 56
Acquas, E., Pisanu, A., Marrocu, P., et al. (2000) · UNICA IRIS Institutional Research Information System (University of Cagliari) · Cited by 56
ADDICTION RESEARCH CENTER INVENTORY (ARCI): DEVELOPMENT OF A GENERAL DRUG ESTIMATION SCALE
Haertzen, C. A. (1965) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196509000-00006 · Cited by 55
Metabolism and disposition of delta-9-tetrahydrocannabinol in man.
Lemberger, L., Axelrod, J., & Kopin, I. J. (1971) · PubMed · Cited by 53
Hollister, L. E. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb08576.x · Cited by 47
Muschamp, J. W., & Siviy, S. M. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00910-3 · Cited by 44
Cannabinoid/Anandamide System and Schizophrenia: Is there Evidence for Association?
Schneider, U., Leweke, F. M., Müller‐Vahl, K., & Emrich, H. M. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979355 · Cited by 43
Porcella, A., GESSA, G. L., & Pani, L. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00175.x · Cited by 38
The psychoactive ingredient of marijuana induces behavioural sensitization
Rubino, T., Viganò, D., Massi, P., & Parolaro, D. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01709.x · Cited by 36
Miyamoto, A., Yamamoto, T., Ohno, M., Watanabe, S., Tanaka, H., Morimoto, S., & Shoyama, Y. (1996) · Brain Research · doi:10.1016/0006-8993(95)01352-0 · Cited by 36
Microprocessor-based assessment of attention deficit disorders (ADD).
Gordon, M. (1986) · PubMed · Cited by 35
Ohlsson, A., Widrnan, M., Carlsson, S., Ryman, T., & Strid, C. (1980) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1980.tb03660.x · Cited by 34
Effects of different cortical excisions on sensory thresholds in man.
Corkin, S., Milner, B. A., & Rasmussen, T. (1964) · PubMed · Cited by 34
Cellular mechanisms of Δ9‐tetrahydrocannabinol behavioural sensitization
Rubino, T., Viganò, D., Massi, P., & Parolaro, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02452.x · Cited by 31
Long-term retention of implicit learning in Huntington's disease
Bylsma, F., Rebok, G. W., & Brandt, J. (1991) · Neuropsychologia · doi:10.1016/0028-3932(91)90035-7 · Cited by 29
Some Features of Cannabis Plants Grown in the United Kingdom from Seeds of Known Origin
Pitts, J. E., Neal, J. D., & Gough, T. A. (1992) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1992.tb07072.x · Cited by 26
Shaw, L. M., Edling-Owens, J., & Mattes, R. D. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.12.2062 · Cited by 23
Levels of processing and acute effects of marijuana on memory
Belmore, S. M., & Miller, L. L. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90073-8 · Cited by 23
Metabolic studies of drugs of abuse.
Volkow, N. D., Fowler, J. S., Wolf, A. P., & Gillespi, H. (1990) · PubMed · Cited by 23
Miyamoto, A., Yamamoto, T., & Watanabe, S. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12189-7 · Cited by 16
Greene, R. J., Brashear, W. T., Auten, K. L., et al. (1992) · Journal of Analytical Toxicology · doi:10.1093/jat/16.1.28 · Cited by 11
Amphetamine psychosis: overview and a hypothesis.
Siomopoulos, V. (1975) · PubMed · Cited by 9
Sadler, B. M., Wall, M. E., & Perez‐Reyes, M. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-044620-9.50021-x · Cited by 3
Research works printed but not linked: 6
- Belger A, Puce A, Krystal JH, Gore JC, Goldman-Rakic P, McCarthy G (1998). Dissociation of mnemonic perceptual processes during spatial nonspatial working memory using fMRI. Hum Brain Mapping 6: 14–32. · DOI · Paper page
- Gold MS (1991). Marijuana In: Miller eNS (ed). Comprehensive Handbook of Alcohol Drug Addiction. Marcel Decker: New York. pp 353–376.
- Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999b). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544–4558. · DOI · Paper page
- Moreau J (1973) In: Peters NGH (ed). Hashish Mental Illness. Raven Press: New York. pp 245.
- Moreau de Tours J (1973). Sobre el hachisch y la alienacion mental. Actas Luso-Espanolas Neurol Psiquiatr Cienc Afines 1: 477–484.
- Wall ME, Brine DR, Perez-Reyes M (1976). Metabolism of cannabinoids in man In: Braude MC, Szara S (eds). Pharmacology of Marihuana Vol 1, pp 536.
Cited by
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Chronic stress, drug use, and vulnerability to addiction
Sinha, R. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.030 · Cited by 1,904
The environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572
Metadata
- Authors
- D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H.
- Affiliations
- Yale University (US)
- Nathan Kline Institute for Psychiatric Research (US)
- Venue
- Neuropsychopharmacology
- Published
- 2004-06-02
- Volume
- 29
- Issue
- 8
- Pages
- 1558-1572
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1996278273
- Cited by
- 1,024
- References
- 143
- Citations by year
- 2026: 28 · 2025: 24 · 2024: 40 · 2023: 45 · 2022: 66 · 2021: 64 · 2020: 91 · 2019: 50 · 2018: 57 · 2017: 61 · 2016: 58 · 2015: 49 · 2014: 55 · 2013: 36 · 2012: 55
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5k02aa000261-04)
- National Center for PTSD, U.S. Department of Veterans Affairs
- National Institute on Alcohol Abuse and Alcoholism (K02 AA00261-04)
- National Institute of Mental Health (R01 MH61019-02, MH 44866, MH61019-02, R01MH061019, P50 MH44866-15, P50MH044866)
- National Institute on Drug Abuse (R01DA012382, 1 DA12382-01)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- delta-9-tetrahydrocannabinol, psychotomimetic effects, psychosis, schizophrenia-like symptoms, positive and negative symptoms, cognitive impairment, working memory, distractibility, verbal fluency, plasma cortisol, anxiety, euphoria, altered perception, cannabinoid receptors, cannabis use, healthy volunteers, drug safety
- MeSH terms
- Adult, Anxiety, Arousal, Attention, Behavior, Cognition, Dose-Response Relationship, Drug, Double-Blind Method, Female, Hallucinogens, Hemodynamics, Humans, Hydrocortisone, Injections, Intravenous, Male, Memory, Short-Term, Panic, Prolactin, Psychiatric Status Rating Scales, Psychometrics, Psychoses, Substance-Induced, Mental Recall, Speech, Dronabinol, Verbal Learning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.